Pulmonx (LUNG) Revenue (2019 - 2025)

Pulmonx (LUNG) has 7 years of Revenue data on file, last reported at $21.5 million in Q3 2025.

• On a quarterly basis, Revenue rose 5.47% year-over-year to $21.5 million in Q3 2025; TTM through Sep 2025 was $91.7 million, a 15.59% increase from a year earlier, with the FY2024 full-year figure at $83.8 million, up 22.01% from the prior year.
• Revenue for Q3 2025 stood at $21.5 million, down from $23.9 million in the prior quarter.
• Over the last five years, Revenue for LUNG reached as high as $23.9 million in Q2 2025 and fell as low as $9.2 million in Q1 2021.
• Historically, Revenue has averaged $17.0 million across 5 years, with a median of $17.2 million in 2023.
• Across the five-year window, Revenue surged 232.24% in 2021 and climbed 1.82% in 2022, its largest moves.
• Year by year, Revenue stood at $13.7 million in 2021, then grew by 12.53% to $15.4 million in 2022, then advanced by 24.98% to $19.3 million in 2023, then gained by 23.28% to $23.8 million in 2024, then fell by 9.52% to $21.5 million in 2025.
• Per Business Quant data, the three most recent Revenue figures were $21.5 million in Q3 2025, $23.9 million in Q2 2025, and $22.5 million in Q1 2025.